ATI at the 20th Annual Non-Dilutive Funding Summit
The 20th Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with representatives from some of the leading funding agencies including DARPA, CDMRP, ATI, NHLBI, NSCEB, NIA and more, giving attendees the opportunity to learn more in-depth about what non-dilutive funding opportunities are available and relevant for their R&D directly from the funding agencies.
Additionally, the 2024 FreeMind Elite honorees took to the stage to present about their companies research and pipelines and their journey to securing non-dilutive funding.
This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences.
Advanced Technology International (ATI)
Advanced Technology International (ATI) is a non-profit organization that plays a pivotal role in advancing life sciences innovation through collaborative partnerships. By managing consortia that bring together government agencies, private industry, and academic institutions, ATI accelerates the development of groundbreaking solutions in healthcare, biotechnology, and medical research. Its streamlined contracting processes and expertise in managing complex R&D projects enable rapid progress in areas such as advanced therapeutics, diagnostics, and biomanufacturing. ATI’s efforts focus on addressing critical challenges in public health and fostering innovations that enhance quality of life and global healthcare resilience.
Dr. Mike Stebbins, Senior Vice President
Dr. Stebbins is Senior Vice President of ATI and oversees the Medical & Threat Countermeasures Division. This Division includes six unique Other Transaction (OT) Agreement programs for HHS and DoD valued at greater than $50B. The HHS portfolio includes BARDA’s Rapid Response Partnership Vehicle (RRPV) and BARDA’s Biopharmaceutical Manufacturing Preparedness – Consortium (BioMaP), as well as ARPA-H’s Customer Experience Hub, part of the ARPANET-H Network. On the DoD side the portfolio includes the Medical Technology Enterprise Consortium (MTEC), the Medical CBRN Defense Consortium (MCDC)) and the Countering Weapons of Mass Destruction Consortium (CWMD).
Mike led the startup of two biotech/health related OT efforts and since inception has led the execution of over $10B of funded prototype development projects through the MCDC and CWMD consortia. He also serves as the Executive Director for both the MCDC and CWMD Consortia, as in his role as the Program Executive for RRPV, Bio-MaP and Customer Experience Hub is guiding the startup of these important new initiatives.
Mike also played a key role in winning and then executing the UI LABS-led Digital Manufacturing and Design Innovation Institute (DMDII, now MxD), one of several Manufacturing Innovation Institutes. Other projects include an effort at Ft. Sumter National Monument to incorporate solar panel technology with hydrogen fuel cells to create an energy production and backup power system and an effort to incorporate landfill gas converted to hydrogen as a fuel to power material handling equipment at BMW’s South Carolina production facility. Finally, Mike was a key participant in ATI’s Copper Touch Surfaces and Copper Air Quality programs — designed to demonstrate and validate that the introduction of copper reduces levels of harmful microbes.
Mike was awarded a Ph.D. in analytical chemistry from the University of Tennessee, Knoxville and a B.S. in chemistry from the College of Charleston.
